Ann: Results of LCT Parkinsons trial require further analysis, page-98

No, if you listen to the open briefing they pretty much got the top line results and presented them unedited asap to comply with the ASX reporting.

They said they haven't had an opportunity to do a post hoc analysis to see if there are any trends or individuals showing interesting responses.

Something I didn't hear mentioned for instance was the base line characteristic related to responsiveness to L-dopa. This is important since it measures the global brain damage caused by dopamine deprivation. So patients who have poor responsiveness have greater damage and would be expected to have less response to other treatments as well. If the study had a significant number of such patients then the response might well be poorer than one with patients who had less damage. Since the trial is small, it wouldn't take much to tip the balance.

So if cohort #2 had patients with less brain damage they could show a better result, not because the 80 unit dose was optimal, but because of the differences in patients baseline characteristics.

Personally though I am not hopeful unless the 52 week and 78 week data show an improving trend. That is certainly possible, but not really worth betting on. Curiously though the monkey data did show improvement which still suggests there is genuinely something useful, but maybe it wasn't the perfect model.